- American City Business Journals•3 hours ago
Drug developer AstraZeneca PLC will bring more than 350 California employees together in the massive Cove at Oyster Point development in South San Francisco, the company said Tuesday. It comes as Big Pharma players, including Merck & Co. Inc., scout local sites in an effort to cozy up to hot, young Bay Area drug developers . The Cove, now in the second phase of construction by HCP Inc. at Highway 101 and Oyster Point Boulevard, already has landed high-profile biotech startups, such as neurodegenerative drug developer Denali Therapeutics Inc. and cancer drug maker CytomX Therapeutics Inc. But AstraZeneca (AZN) could dwarf those companies with its expected fourth-quarter 2017 move-in.
- TheStreet.com•12 hours ago
A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
- Investor's Business Daily•yesterday
The FDA could approve a breakthrough adult eczema treatment from Regeneron and Sanofi as soon as March.
AstraZeneca PLC (AZN)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||33.60 x 10300|
|Ask||33.61 x 2400|
|Day's Range||32.98 - 33.63|
|52wk Range||26.97 - 35.04|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||38.41|
|Avg Vol (3m)||6,026,818|
|Dividend & Yield||0.90 (2.65%)|